DIA: Driving Insights to Action

HSA Harmonizing Culture and Science in Singapore

With more than 30 leading multinational pharmaceutical companies choosing Singapore as their base for operations in this region, this island nation has emerged as one of the most advanced biomedical R&D hubs in Asia. “The Singapore government understands the importance for Singapore, as a small country, to follow international standards,” explains Jin Shun, Head of Regulatory Affairs, Asia-Pacific, Middle East and Africa, for Sandoz, a Unit of Novartis. “HSA (the Health Sciences Authority) joined ICH in November 2017, and announced the implementation of eCTD at the end of last year.” Mr. Shun serves on the program committee for the DIA-CoRE Singapore Annual Meeting 2019.

Promoting Patient-Centric Business: MedComm in Latin America

Barbara Nardi, Associate Director of Medical Communications, PPD (Brazil), and Emanuela Lopes Fernandes Saraiva, Customer Service & Medical Information Manager in Pharmacovigilance, Libbs Farmaceutica (Brazil), discuss topics from DIA’s first Latin America Medical Information and Communication Workshop. “The biggest challenge we have is capturing the patient voice and promoting the patient-centric future at the core of the business model,” suggests Emanuela.

Separate but Equal: Regulatory & Pricing Assessments in EU

Dr. Esa Heinonen is Director, Assessment of Medicinal Products, for the Finnish Medicines Agency, and Co-Chair of the EU Innovation Network, established in 2016 “to facilitate the development of innovative medicines by addressing gaps in early regulatory support to innovation.” Dr. Heinonen discusses How Can the EU Regulatory Network Support Innovation?, the title of the session that he will chair at DIA Europe 2019.